🏛️ Verified NIH Record • Updated 2025-09-24

An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis (NCT01357668)

🔵 Active, Not Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: Bristol-Myers Squibb

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to examine the long-term safety of Abatacept for the treatment of juvenile idiopathic arthritis (JIA) with particular in interest in the occurrence of serious infections, autoimmune disorders, and malignancies.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (4 items) and avoid the listed exclusions (5 items).

Location: Local Institution - 0060 — Little Rock, Arkansas

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria
  • Pregnant or nursing female at the time of enrollment
  • Prior malignancies if the patient has not been malignancy free for at least 5 years.
  • Any serious acute or chronic medical condition other than JIA, including chronic infection, which would compromise the patient's ability to participate in the study
  • Known poor compliance with clinic visits (based on physician judgment).

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (59 Sites)

  • Local Institution - 0060 — Little Rock, Arkansas
  • Local Institution - 0001 — Princeton, New Jersey
  • Local Institution - 0059 — Cincinnati, Ohio
  • Local Institution - 0025 — Bregenz,
  • Local Institution - 0002 — Innsbruck,
  • Local Institution - 0032 — Vienna,
  • Local Institution - 0010 — Botucatu, São Paulo
  • Local Institution - 0026 — Campinas, São Paulo
  • Local Institution - 0028 — São Paulo, São Paulo
  • Local Institution - 0027 — Rio de Janeiro,
  • Local Institution - 0029 — Calgary, Alberta
  • Local Institution - 0011 — Montreal, Quebec
  • Local Institution - 0035 — Aarhus, Central Jutland
  • Local Institution - 0012 — Copenhagen,
  • Local Institution - 0040 — Clermont-Ferrand, Puy-de-Dôme
  • Local Institution - 0005 — Paris,
  • Local Institution - 0041 — Toulouse,
  • Local Institution - 0003 — Bad Bramstedt,
  • Local Institution - 0030 — Berlin,
  • Local Institution - 0034 — Freiburg im Breisgau,
  • Local Institution - 0031 — Hamburg,
  • Local Institution - 0033 — Heidelberg,
  • Local Institution - 0016 — Thessaloniki,
  • Local Institution - 0017 — Budapest,
  • Local Institution - 0014 — Jerusalem,

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗